Your Annual Touchpoint with the Global RNA-Targeted Industry to Foster New & Existing Relationships
As the RNA-targeting field evolves beyond traditional splice modulation, biopharma innovators are exploring covalent modifiers, proximity-based strategies, and novel structural targets to unlock next-generation therapies. With pipelines expanding, there is a growing demand for specialized partners to accelerate drug development from bench to bedside.
Returning to Boston, the 8th RNA-Targeted Drug Discovery & Development Summit is your premier opportunity to connect with key decision-makers from leading biopharma companies, including J&J, PTC Therapeutics, Arrakis Therapeutics, ReviR Therapeutics, Remix Therapeutics, and more.
Join 80+ senior-level experts actively seeking cutting-edge solutions across small molecule libraries, target engagement assays, chemical characterization and synthesis, RNA sequencing, NMR, Cryo-EM and in silico modeling to support their RNA target structure understanding and improve their preclinical safety and efficacy studies.
Position your brand as a trusted partner in this rapidly advancing space. Forge lasting relationships, showcase your capabilities, and unlock new business opportunities in RNA-targeted drug development.
Who will you meet?


Key Interest Areas
Our attendees from are looking for service and solution providers with capabilities in the below areas but not limited to:

Small Molecule Screening Libraries

Target engagement and fluorescent tagging assays for RNA

Chemical characterization and synthesis of small molecules

RNA structural analysis including NMR, Cryo-EM, X-ray crystallography and AI/in-silico modeling

NGS and HTS RNA sequencing services

Mass spectrometry and other proteomic techniques
Any questions? Curious to know more about the range of partnership opportunities? Want to understand what your partnership with Hanson Wade could look like?